No, that's why the bump was small. It will take the results from the Ponatinib vs Nilotinib head to head study to impact the,black box warning, unless the recent meta-analysis across the,three 2nd Gen TKI that showed comparable cardiovascular risks is enough to convince FDA.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.